MX379622B - Compuestos espirociclicos - Google Patents
Compuestos espirociclicosInfo
- Publication number
- MX379622B MX379622B MX2017012553A MX2017012553A MX379622B MX 379622 B MX379622 B MX 379622B MX 2017012553 A MX2017012553 A MX 2017012553A MX 2017012553 A MX2017012553 A MX 2017012553A MX 379622 B MX379622 B MX 379622B
- Authority
- MX
- Mexico
- Prior art keywords
- spirocyclic compounds
- compounds
- spirocyclic
- ameliorating
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562142946P | 2015-04-03 | 2015-04-03 | |
| PCT/US2016/025345 WO2016161160A1 (en) | 2015-04-03 | 2016-03-31 | Spirocyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017012553A MX2017012553A (es) | 2018-04-11 |
| MX379622B true MX379622B (es) | 2025-03-11 |
Family
ID=57007413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012553A MX379622B (es) | 2015-04-03 | 2016-03-31 | Compuestos espirociclicos |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10525036B2 (enExample) |
| EP (1) | EP3277690B1 (enExample) |
| JP (1) | JP6737533B2 (enExample) |
| KR (1) | KR20170132307A (enExample) |
| CN (1) | CN107849053B (enExample) |
| AU (1) | AU2016242940B2 (enExample) |
| BR (1) | BR112017021194A2 (enExample) |
| CA (1) | CA2981055A1 (enExample) |
| CY (1) | CY1123019T1 (enExample) |
| DK (1) | DK3277690T3 (enExample) |
| ES (1) | ES2788160T3 (enExample) |
| HR (1) | HRP20200805T1 (enExample) |
| HU (1) | HUE049481T2 (enExample) |
| IL (1) | IL254662B (enExample) |
| LT (1) | LT3277690T (enExample) |
| MX (1) | MX379622B (enExample) |
| PL (1) | PL3277690T3 (enExample) |
| PT (1) | PT3277690T (enExample) |
| RS (1) | RS60340B1 (enExample) |
| RU (1) | RU2745069C2 (enExample) |
| SG (1) | SG11201707911VA (enExample) |
| SI (1) | SI3277690T1 (enExample) |
| SM (1) | SMT202000279T1 (enExample) |
| TW (1) | TWI705067B (enExample) |
| WO (1) | WO2016161160A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106999451B (zh) * | 2014-09-17 | 2021-04-02 | 里科瑞尔姆Ip控股有限责任公司 | 双环化合物 |
| EP3277690B1 (en) | 2015-04-03 | 2020-02-26 | Recurium IP Holdings, LLC | Spirocyclic compounds |
| KR20190075931A (ko) | 2016-10-05 | 2019-07-01 | 제노 로얄티즈 앤 마일스톤즈, 엘엘씨 | 스피로 고리 화합물 |
| CA3045947A1 (en) * | 2016-12-08 | 2018-06-14 | Michael J. Soth | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease |
| JP2021512109A (ja) * | 2018-01-31 | 2021-05-13 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用 |
| EP3956330A4 (en) | 2019-04-18 | 2023-01-18 | The Johns Hopkins University | SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE |
| US11560366B2 (en) | 2019-10-21 | 2023-01-24 | Board Of Regents, The University Of Texas System | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease |
| IL301817A (en) | 2020-10-13 | 2023-06-01 | Univ Johns Hopkins | Modified 4-([4,2,1]triazolo[5,1-a]pyridin-6-yl)thiophene-2-carboxamide histories and their use |
| CN115124542A (zh) * | 2022-07-08 | 2022-09-30 | 河南师范大学 | 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR057579A1 (es) * | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
| US8546404B2 (en) * | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| JP5380296B2 (ja) | 2006-11-17 | 2014-01-08 | ポリエラ コーポレイション | ジイミド系半導体材料ならびにジイミド系半導体材料を調製および使用する方法 |
| CN102015693B (zh) * | 2008-02-21 | 2014-10-29 | 默沙东公司 | 作为erk抑制剂的化合物 |
| EP2318388A2 (en) | 2008-07-23 | 2011-05-11 | Schering Corporation | Tricyclic spirocycle derivatives and methods of use thereof |
| CA2774769A1 (en) * | 2009-09-30 | 2011-04-07 | Schering Corporation | Novel compounds that are erk inhibitors |
| CA3044884A1 (en) | 2009-12-07 | 2011-06-16 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| WO2013033059A1 (en) | 2011-08-29 | 2013-03-07 | Bristol-Myers Squibb Company | Spiro bicyclic diamine derivatives as hiv attachment inhibitors |
| CN103130775B (zh) * | 2011-11-22 | 2015-09-30 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 |
| US8987264B2 (en) * | 2012-11-09 | 2015-03-24 | Bristol-Myers Squibb Company | 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C |
| US9447025B2 (en) | 2013-03-14 | 2016-09-20 | Kalyra Pharmaceuticals, Inc. | Bicyclic analgesic compounds |
| CN105732636B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| EP3277690B1 (en) | 2015-04-03 | 2020-02-26 | Recurium IP Holdings, LLC | Spirocyclic compounds |
| KR20190075931A (ko) | 2016-10-05 | 2019-07-01 | 제노 로얄티즈 앤 마일스톤즈, 엘엘씨 | 스피로 고리 화합물 |
-
2016
- 2016-03-31 EP EP16774232.9A patent/EP3277690B1/en active Active
- 2016-03-31 MX MX2017012553A patent/MX379622B/es unknown
- 2016-03-31 RS RS20200577A patent/RS60340B1/sr unknown
- 2016-03-31 JP JP2017552060A patent/JP6737533B2/ja not_active Expired - Fee Related
- 2016-03-31 RU RU2017133973A patent/RU2745069C2/ru active
- 2016-03-31 HU HUE16774232A patent/HUE049481T2/hu unknown
- 2016-03-31 PL PL16774232T patent/PL3277690T3/pl unknown
- 2016-03-31 US US15/563,926 patent/US10525036B2/en not_active Expired - Fee Related
- 2016-03-31 ES ES16774232T patent/ES2788160T3/es active Active
- 2016-03-31 LT LTEP16774232.9T patent/LT3277690T/lt unknown
- 2016-03-31 PT PT167742329T patent/PT3277690T/pt unknown
- 2016-03-31 SG SG11201707911VA patent/SG11201707911VA/en unknown
- 2016-03-31 CA CA2981055A patent/CA2981055A1/en not_active Abandoned
- 2016-03-31 WO PCT/US2016/025345 patent/WO2016161160A1/en not_active Ceased
- 2016-03-31 BR BR112017021194A patent/BR112017021194A2/pt not_active IP Right Cessation
- 2016-03-31 SI SI201630764T patent/SI3277690T1/sl unknown
- 2016-03-31 HR HRP20200805TT patent/HRP20200805T1/hr unknown
- 2016-03-31 KR KR1020177031578A patent/KR20170132307A/ko not_active Ceased
- 2016-03-31 AU AU2016242940A patent/AU2016242940B2/en not_active Ceased
- 2016-03-31 DK DK16774232.9T patent/DK3277690T3/da active
- 2016-03-31 SM SM20200279T patent/SMT202000279T1/it unknown
- 2016-03-31 CN CN201680028591.0A patent/CN107849053B/zh not_active Expired - Fee Related
- 2016-04-01 TW TW105110691A patent/TWI705067B/zh not_active IP Right Cessation
-
2017
- 2017-09-25 IL IL254662A patent/IL254662B/en active IP Right Grant
-
2019
- 2019-03-15 US US16/354,949 patent/US10493060B2/en not_active Expired - Fee Related
-
2020
- 2020-01-06 US US16/734,857 patent/US20200268714A1/en not_active Abandoned
- 2020-04-10 CY CY20201100356T patent/CY1123019T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019003938A (es) | Compuestos espirociclicos. | |
| ZA201807399B (en) | Egfr inhibitor compounds | |
| MX392368B (es) | Composiciones y metodos para el tratamiento del cancer | |
| MX2021000710A (es) | Composiciones que comprenden cepas bacterianas. | |
| IL268469B (en) | 2-Heteroaryl-3-oxo-3,2-dihydropyridazine-4-carboxamides for cancer treatment | |
| PH12017501999A1 (en) | K-ras modulators | |
| MX2017001587A (es) | Terapia de combinacion para tratar un paramixovirus. | |
| MX2017014436A (es) | Compuestos biciclicos. | |
| MY187540A (en) | Compounds active towards bromodomains | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| EP3800248A3 (en) | Crispr-cas-related methods, compositions and components for cancer immunotherapy | |
| EP4193993A3 (en) | Combinations of cannabinoids and n-acylethanolamines | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| MA40457A (fr) | Combinaison de médicaments pour traiter le myélome multiple | |
| MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
| MX2017012553A (es) | Compuestos espirociclicos. | |
| HK1254231A1 (zh) | 米托-和厚朴酚化合物及其合成方法和用途 | |
| MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
| WO2016130581A3 (en) | Combination cancer therapy | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| EP4541423A3 (en) | Dosing regimen of avelumab for the treatment of cancer | |
| MX2019009199A (es) | Composiciones y métodos para modular ppp2r1a. | |
| PH12017500071A1 (en) | Therapeutic agent for keratoconjunctive disorder | |
| HUE057090T2 (hu) | BI-heteroaril-szubsztituált 1,4-benzodiazepinek és alkalmazásuk rák kezelésében |